Connect with us

Hi, what are you looking for?

Economy

Are vaccines variant-proof? Here’s some good news

SCIENCE has delivered some incredible achievements in the fight against COVID-19, not least of which is the swift development of several highly effective vaccines. The question is, will the shots continue to offer strong protection even as the SARS-CoV-2 virus mutates and evolves?

We’ve already seen virus variants sprout up, from B.1.1.7 in the UK to B.1.351 in South Africa and P.1 in Brazil. Now we have B.1.617 in India and two variants — B.1.429 and B.1.232 — in California. Some of these variants have been found to be more contagious and potentially deadlier than the original strain, and more variants are sure to arise in any country or region where the virus is left to multiply and infect people at a high rate. Even in places where the virus seems to be under control, variants are a worry. In Israel, there have been reports of “breakthrough” infections among vaccinated people, mostly of the B.1.351 variant. These are big concerns. But there are hopeful signs that vaccine science is staying ahead of the variants in the most important ways.

First, some good news regarding potential “booster” shots. A recent study found that a new vaccine targeting the “spike protein” — the rod-like structure on the surface of the virus — of the South African variant induced a strong immune response in nonhuman primates that had been previously vaccinated against the older virus strain. Moderna, Inc. has also noted, though not published data, that its new mRNA-1273.351 vaccine was able to boost the immune response of previously vaccinated animals to provide increased activity against the B.1.351 variant.

These two studies address a key concern I had around the risk of “original antigenic sin” — that is, that a new vaccine against a slightly different virus variant might induce an immune reaction against the original version of the virus rather than the variant it was targeting. While we need to see data from a human study, which Moderna could have sometime in the second quarter, these results suggest we are one step closer to having a variant vaccine, should we need one.

As for existing vaccines, promising new data suggests that the shot now in use from Pfizer, Inc. and BioNTech SE is effective in protecting against variants. Results from a small South African trial of the Pfizer-BioNTech vaccine showed 100% efficacy against the B.1.351 variant. Though based on only a few cases, it showed that none of those who were vaccinated as part of the trial tested positive, compared with nine who contracted the virus while taking a placebo (six of whom contracted the South African variant). It’s possible that the vaccinated group didn’t encounter the virus and a lot more cases are needed to draw a firm conclusion, but this early data suggests the efficacy against this variant is robust. This may explain why Pfizer and BioNTech have decided to use their original vaccine as a third booster, if it proves necessary, and not develop a shot using the spike protein from the B.1.351 variant.

But what about that news from Israel about breakthrough infections? In a nutshell, I am not that worried about it. We already knew that the vaccines can’t stop all infections. We also knew from several studies by different groups that the B.1.351 variant is not as susceptible to the antibodies generated by the Pfizer-BioNTech or Moderna vaccines as the ancestral versions of the virus are. So infections in vaccinated people in areas where the variant is circulating would be more likely to be by the B.1.351 variant than not. But while people may get infected by variants despite being vaccinated, the critical point is whether they develop anything but mild symptoms. What we truly care about is severe COVID-19 disease and hospitalizations. If all the infected individuals had only mild symptoms, or none at all, then that actually proves the point: The vaccine is doing its job in preventing severe disease and hospitalizations. This appears to be the case.

I am not suggesting that we stop worrying about variants. As I have written before, there needs to be much more genomic sequencing across the world to ensure we are on top of any changes in the virus. But we need not panic. Variants occur when the virus is multiplying at high levels. Having a fully vaccinated population significantly reduces its chances of doing that. What we do need to do is to get vaccines faster to the nations that cannot afford them.

BLOOMBERG OPINION

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Get the daily email that makes reading the news actually enjoyable. Stay informed and entertained, for free.
Your information is secure and your privacy is protected. By opting in you agree to receive emails from us. Remember that you can opt-out any time, we hate spam too!

Latest

Economy

By Diego Gabriel C. Robles THE COUNTRY’S Socioeconomic Planning chief on Monday belittled the peso’s free fall against the dollar, saying there is nothing...

Economy

By Kyle Aristophere T. Atienza, Reporter SAN MIGUEL CORP. would proceed with building an international airport north of the Philippine capital even after a...

Economy

FELIPE M. MEDALLA / COURTESY OF BANGKO SENTRAL NG PILIPINAS PHILIPPINE CENTRAL BANK Governor Felipe M. Medalla would continue the “game-changing” reforms of the...

Economy

RAZON-LED Prime Infrastructure Capital, Inc. through its unit WawaJVCo, Inc. announced that it completed the Tayabasan weir, which is the first phase of its...

Economy

FRUITAS Holdings, Inc. plans to use part of its one-time gain from selling existing shares in subsidiary Balai ni Fruitas, Inc. to fund its...

Economy

LISTED construction company Megawide Construction Corp. announced on Monday that it secured its eighth contract with housing developer PHirst Park Homes, Inc. (PPHI). Under...

You May Also Like

Investing

Having a good Instagram marketing agency to back up your Instagram account is an absolute must going into the new year. With competition stronger...

Economy

Ivermectin, an existing drug against parasites including head lice, has had a checkered history when it comes to treating COVID-19. The bulk of studies...

Investing

Insomnia is the most common sleep disorder in the global population. Therefore, it is a problem that many people suffer or have suffered throughout...

Investing

As a traditionally rigid insurance industry becomes bogged down by antiquated processes and operations, a handful of industry leaders are seeking to shake things...

Disclaimer: SmartRetirementReport.com, its managers, its employees, and assigns (collectively "The Company") do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

Copyright © 2021 SmartRetirementReport. All Rights Reserved.